影响下肢血管内介入术后抗血栓药物处方的患者因素
该研究通过离散选择实验问卷,调查澳大利亚与新西兰血管外科医生及学员在下肢外周动脉疾病血管内介入术后选择抗血栓药物的决策因素。共完成44份问卷,结果显示股腘动脉支架置入后比球囊血管成形术后更可能处方第二种抗血栓药(OR 1.89,95%CI 1.20-2.13),慢性肢体威胁性缺血比间歇性跛行更可能处方第二种抗血栓药(OR 1.58,95%CI 1.20-2.13)。多数受访者首选氯吡格雷而非利伐沙班(62%)。
要点
- 股腘动脉支架置入后比球囊血管成形术后更可能处方第二种抗血栓药(OR 1.89,95%CI 1.20-2.13)。
- 慢性肢体威胁性缺血比间歇性跛行更可能处方第二种抗血栓药(OR 1.58,95%CI 1.20-2.13)。
- 多数受访者首选氯吡格雷而非利伐沙班作为阿司匹林外的第二种抗血栓药(62%)。
核心结论
- 血管外科医生主要根据手术类型优先决定抗血栓药物处方。
- 氯吡格雷比利伐沙班更常被处方为与阿司匹林联用的第二种药物,尤其在支架置入后。
- 了解这些临床偏好有助于针对不同风险特征的患者亚组制定决策支持策略。
研究设计与样本
- 向澳大利亚与新西兰血管外科学会300名血管外科医生及学员成员发放离散选择实验问卷。
- 2023年9月至10月期间共完成44份问卷,达到15%的目标应答率。
- 采用多项逻辑回归模型分析影响处方第二种抗血栓药物决策的患者因素,以及阿司匹林100 mg每日一次基础上联用氯吡格雷75 mg每日一次或利伐沙班2.5 mg每日两次的偏好选择。
- 以比值比(OR)及95%置信区间(CI)报告偏好强度。
主要发现
- 股腘动脉支架置入后比球囊血管成形术后更可能处方第二种抗血栓药(OR 1.89,95%CI 1.20-2.13)。
- 慢性肢体威胁性缺血比间歇性跛行更可能处方第二种抗血栓药(OR 1.58,95%CI 1.20-2.13)。
- 多数受访者首选氯吡格雷而非利伐沙班(62%),超过三分之一的受访者仅处方氯吡格雷。
- 支架置入患者(OR 1.77,95%CI 1.32-2.37)或中度出血风险患者(OR 1.38,95%CI 0.97-1.84)更可能接受氯吡格雷而非利伐沙班。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: There is significant practice variation in the use of antithrombotic therapy after endovascular intervention for lower limb peripheral arterial disease, with differences in medication choice and duration. Prescriber decision making is complex, and patient factors have been shown to substantially contribute to prescribing variation. To determine the influence of patient factors on antithrombotic prescribing, a discrete choice experiment was distributed to vascular surgeons and trainees across Australia and Aotearoa New Zealand. METHODS: After pilot testing, the discrete choice experiment questionnaire was distributed to 300 vascular surgeons and trainee members of the Australian and New Zealand Society for Vascular Surgery. Multinomial logistic regression models were used to analyse patient factors that had the most influence on decisions to prescribe a second antithrombotic agent, and the preferred choice of antithrombotic (clopidogrel 75 mg daily or rivaroxaban 2.5 mg twice daily) in addition to aspirin 100 mg daily. The odds ratio (OR) with 95% confidence interval (CI) reported preference strength. RESULTS: A total of 44 questionnaires were completed between September and October 2023, reaching the 15% targeted response rate. Prescribing a second antithrombotic was more likely after femoropopliteal stenting compared with angioplasty (OR 1.89, 95% CI 1.20 - 2.13), and in chronic limb threatening ischaemia compared with intermittent claudication (OR 1.58, 95% CI 1.20 - 2.13). Most respondents preferred clopidogrel over rivaroxaban (62%), with over a third of respondents exclusively prescribing clopidogrel. Patients with stents (OR 1.77, 95% CI 1.32 - 2.37) or moderate bleeding risk (OR 1.38, 95% CI 0.97 - 1.84) were more likely to receive clopidogrel than rivaroxaban. CONCLUSION: This study demonstrates that vascular surgeons primarily prioritise antithrombotic prescribing decisions by procedure type. Clopidogrel is more likely to be prescribed than rivaroxaban as a second agent in combination with aspirin, especially after stenting. Knowing these clinician preferences can target implementation strategies towards supporting decision making in subgroups of patients according to individual risk profiles.
引用
- Zhu A, Rajendran S, Hajian H, et al. Patient Factors Influencing Prescription of Antithrombotic Medication After Lower Limb Endovascular Intervention. Eur J Vasc Endovasc Surg. 2024. PMID: 38802038. doi:10.1016/j.ejvs.2024.05.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。